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Background: The fragile X syndrome (FXS) results from mutation of the FMR1 gene that prevents expression of its
gene product, FMRP. We previously characterized 215 dried blood spots (DBS) representing different FMR1
genotypes and ages with a Luminex-based immunoassay (qFMRP). We found variable FMRP levels in the normal
samples and identified affected males by the drastic reduction of FMRP.
Methods: Here, to establish the variability of expression of FMRP in a larger random population we quantified
FMRP in 2,000 anonymous fresh newborn DBS. We also evaluated the effect of long term storage on qFMRP by
retrospectively assaying 74 aged newborn DBS that had been stored for 7-84 months that included normal and full
mutation individuals. These analyses were performed on 3 mm DBS disks. To identify the alleles associated with the
lowest FMRP levels in the fresh DBS, we analyzed the DNA in the samples that were more than two standard
deviations below the mean.
Results: Analysis of the fresh newborn DBS revealed a broad distribution of FMRP with a mean approximately
7-fold higher than that we previously reported for fresh DBS in normal adults and no samples whose FMRP level
indicated FXS. DNA analysis of the lowest FMRP DBS showed that this was the low extreme of the normal range
and included a female carrying a 165 CGG repeat premutation. In the retrospective study of aged newborn DBS,
the FMRP mean of the normal samples was less than 30% of the mean of the fresh DBS. Despite the degraded
signal from these aged DBS, qFMRP identified the FXS individuals.
Conclusions: The assay showed that newborn DBS contain high levels of FMRP that will allow identification of
males and potentially females, affected by FXS. The assay is also an effective screening tool for aged DBS stored for
up to four years.
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Newborn screeningBackground
Fragile X syndrome, the most common inherited cause
of intellectual disability, results from mutation of the
FMR1 gene on the X chromosome that disrupts expres-
sion of the fragile X mental retardation protein (FMRP)
[1,2]. Although there are very rare cases in which the
fragile X syndrome is due to point mutation or deletion
of the FMR1 gene [3-7], the most common fragile X mu-
tation eliminates FMRP expression through expansion of
a CGG repeat in the 5’-untranslated region of FMR1 to* Correspondence: giuseppe.x.lafauci@opwdd.ny.gov
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unless otherwise stated.more than 200 triplets (the full mutation). Although the
fragile X syndrome results directly from the absence of
functional FMRP, diagnosis of this syndrome is based on
allele size and detection of the full mutation expansion
in genomic DNA.
FMR1 alleles are sorted into four size categories based
on their stability upon transmission: normal (up to 44
CGG repeats): intermediate (45-54 repeats); premutation
(55-200 repeats); and full mutation (>200 repeats). In
the North American population the full-mutation allele
(>200 repeats) which is exclusively maternally inherited,
has an approximate prevalence of 1 in 4,000 while the
premutation is much more common with a prevalence
of 1 in 151 females and 1 in 468 males [8]. The premuta-
tion can expand to the full mutation when transmittedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sion is dependent on the length and structure of the allele.
The majority of premutation alleles are less than 90 triplet
repeats in length. FMRP expression is reduced as triplet
repeat length increases from the normal range and is eli-
minated by a process analogous to X inactivation when
the repeat exceeds approximately 200 copies [9,10].
Since males carry only a single X chromosome, those
with a full mutation allele develop the fragile X syn-
drome due to the absence of FMRP. Approximately 40%
of males with the full mutation have some somatic cells
with smaller alleles from triplet repeat contractions dur-
ing early embryogenesis. These alleles express FMRP but
only rarely does this mosaic expression ameliorate the
syndrome. Contractions are also presumably responsible
for the premutation size alleles in the sperm of full muta-
tion males [11]. Large premutation alleles (approximately
150-200 repeats) are associated with intellectual impair-
ment due presumably to reduced FMRP expression.
Females carry two X chromosomes and two copies of
the FMR1 gene, only one of which is expressed in any par-
ticular somatic cell after X inactivation during early em-
bryogenesis. When FMRP expression is reduced because
one FMR1 allele in a female carries the full mutation, the
degree of impairment can range from undetectable to
severe. This variability is due to variation in random X in-
activation and the resulting mosaic distribution of somatic
cells in which FMRP is expressed. Since the full mutation
must be maternally inherited, homozygous full mutation
females do not occur. As in males, mosaicism for smaller
alleles occurs in females but it is more rarely observed.
We recently reported the development of a simple, ac-
curate, and inexpensive capture immunoassay that deter-
mines the level of FMRP in dried blood spots (DBS) as
well as in lymphocytes and other tissues [12]. Our initial
study of FMRP in DBS from 215 individuals with nor-
mal, premutation, and full-mutation FMR1 alleles was
designed to characterize the FMRP expression of dif-
ferent FMR1 genotypes. In samples from normal indi-
viduals we found a broad distribution of FMRP. The
level of the protein declined with age from infants to
preteens. It leveled off in teenage years and remained
unchanged through adulthood, with no difference bet-
ween males and females. We used these DBS samples to
evaluate how effectively this assay distinguished affected
from unaffected individuals. While the assay readily
identified affected (full-mutation) males with sensitivity
and specificity approaching 100%, we needed to test a
larger set of random population samples to establish the
FMRP variability detected by the assay. Since residual
DBS from state-mandated newborn screening for meta-
bolic and genetic diseases are available for research and
represent a uniform age, we decided to use 2,000
randomly selected anonymous fresh newborn DBS tocharacterize the variability of FMRP expression in the
newborn population which is a potential target for
screening with this assay. Considering the estimated
prevalence of fragile X, it was relatively unlikely that we
would find any affected individuals (i.e. those with virtu-
ally no FMRP) among the 1,000 male and 1,000 females
sampled. We were primarily interested, however, in the
variability of FMRP expression, especially the low ex-
treme of normal expression.
To evaluate the effect of long term storage of newborn
DBS on the qFMRP assay, we conducted a retrospective
study of 74 aged newborn DBS that had been stored for
up to 7 years. These DBS were from a different newborn
screening program and included samples from 6 affected
(full mutation) males.
Methods
Newborn DBS disks (3-mm-diameter; ~7.1 mm2) were
obtained from the New York State Department of Health’s
Wadsworth Center, Albany, NY, USA and the New South
Wales Newborn Screening Program, Sydney, Australia.
Studies performed with both sets of disks were reviewed
and approved by the Institutional Review Boards of the
Institute for Basic Research in Developmental Disabilities
(IBR) and the DBS source institutions.
Newborn DBS from the Wadsworth center in New York
State
The DBS disks from 1,000 males and 1,000 females were
recent (5 weeks old) and stored with a desiccant in a re-
frigerator at 2-8°C. They were received (in duplicate) in
sealed 96-well plates with no identifying information
except gender.
Newborn DBS from New South Wales (Australia) newborn
screening program
The seventy-four disks from DBS that had been stored for
7 to 84 months included samples from 6 males diagnosed
with the fragile X syndrome and 68 normal individuals.
The samples from 6 affected males had been stored from
19 to 79 months at low humidity and 22-28°C for 12
months and then at 20°C before FMRP quantification.
Those from 68 normal controls had been stored from 7 to
84 months. Information about phenotype, gender, and age
of DBS was not known by the researchers performing
qFMRP analysis until completion of the study.
Elution of FMRP from DBS
Each 3-mm-diameter disk was placed into a well of a
Low Protein Binding Durapore R Multiscreen 96-well
filter plate (Millipore, Billerica, MA) and protein was
eluted in 50 uL of extraction reagent: M-PER mam-
malian protein extraction reagent (Thermo Fisher
Scientific, Rockford, IL) containing 150 mmol/L NaCl,
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tease inhibitor cocktail (Complete mini tablets, EDTA
free; Roche Applied Science, Indianapolis, IN) by sha-
king for 3 hr with agitation at room temperature.
Eluates were collected by centrifugation at 4°C into a
96-well catch plate for 5 minutes at 1258 × g [12].qFMRP assay procedure
FMRP assays were performed with the anti-FMRP
mouse monoclonal antibody mAb6B8 (MMS-5231,
Covance Inc., Dedham, MA) and the anti-FMRP rabbit
polyclonal antibody R477 [12]. These antibodies are
highly specific and each recognizes a different epitope
of the protein [12]. A GST fusion protein, GST-SR7
carrying an abbreviated sequence of FMRP that in-
cludes the epitopes of mAb6B8 and R477 was used as
standard [12]. The immunoassays were performed as pre-
viously described [12]. Briefly, 50 uL DBS eluate was incu-
bated for 6 hr with 3,000 xMAP-MicroPlex microspheres
(Luminex, Austin, TX) coupled to anti-FMRP mAb6B8.
The microspheres were then washed and incubated over-
night with rabbit antibody, R477 that was subsequently la-
beled for 2 hr by phycoerythrin-conjugated goat anti-rabbit
IgG. FMRP was quantified with a Luminex 200 system.
Dilutions of GST-SR7 were used to generate an FMRP
standard concentration curve for each 96-well plate ana-
lyzed. The amount of FMRP in the DBS was reported as
concentration (pM) in the 50 uL DBS eluate.Figure 1 Distribution of FMRP levels in 2,000 newborn DBS
from the NY State collection. The mean FMRP value was 44.8 pM;
standard deviation 12.4 pM; skewness 1.11; kurtosis 3.175.DNA studies
DNA was eluted from approximately ½ of a duplicate
3mm (~3.5 mm2) disk by the following modification of
a published procedure [13].The DBS disk was initially
washed in 1 mL of SSPE (0.15 M NaCl, 0.01M
NaH2PO4 pH 7.0, and 0.001M EDTA) containing 0.1%
Tween 80 (Sigma-Aldrich, St Louis, MO 63103 USA)
for 10 minutes at room temperature and the half disk
was transferred to 100 μL of 5% Chelex (BioRad,
Hercules, CA 94547 USA) in H2O, incubated for 30
min at 60°C and then for 30 min at 100°C. The liquid
phase was separated from the Chelex and brought to 1
mM EDTA. Two microliters of this eluate served as
template for polymerase chain reaction (PCR) am-
plification of the FMR1 CGG repeat region with the
AmplideX® FMR1 PCR (RUO) reagents according to
the manufacturer’s directions (Asuragen, Austin, TX
78744 USA). PCR products were analyzed by capillary
electrophoresis (ABI 3130 Genetic Analyzer, Applied
Biosystems, Foster City, CA) [14]. This eluate was
also used for analysis of DNA methylation in the
FMR1 CGG repeat region with the Amplidex® FMR1
mPCR kit according to the manufacturer’s directions
(Asuragen, Austin, TX 78744 USA).Statistical analysis
Data were analyzed with either IBM SPSS Statistics
(IBM, Armonk, NY) or SigmaPlot (Systat Software, San
Jose, CA) software.
Results
NY State newborn DBS samples
We applied the qFMRP immunoassay to 1,000 male and
1,000 female newborn DBS that had been stored for only
five weeks (fresh DBS). FMRP concentration (pM) in
each sample (3-mm-diameter disk eluate) was calculated
by comparison to dilutions of GST-SR7 as previously de-
scribed [12]. The results showed a variable expression of
FMRP ranging from 10.3- to 92-pM, an average FMRP
of 44.8 pM, and a SD of 12.4 pM (Figure 1). Comparison
of the FMRP levels obtained in this study to those re-
ported previously [12] for normal adults using larger
DBS disks (6.9-mm-diameter, 37.4 mm2) revealed that,
the average FMRP in newborn was approximately seven-
fold higher (6.3 pM eluted per mm2) than in adults (0.93
pM eluted per mm2). None of the 1,000 male or 1,000
female random newborn DBS lacked FMRP or had the
extremely low level that would indicate the fragile X syn-
drome [12].
To examine the FMR1 genotypes of the samples at the
low extreme of the FMRP distribution, we extracted gen-
omic DNA from duplicate DBS of the 14 samples whose
level of FMRP was more than two standard deviation
units below the newborn population mean and deter-
mined the size of the CGG repeat in the FMR1 alleles
that were present (Table 1). The alleles detected in the
14 DBS samples (0.7%) that met this criterion are shown
in Table 1. Thirteen of the samples showed an assort-
ment of normal FMR1 CGG repeat alleles that reflects
the allele distribution in the normal population which
Table 1 NY State newborn DBS with lowest FMRP levels
Sample FMRP(pM) Z# Sex Allele 1 Allele 2 Allele 3
1 10.3 −2.8 f 32 44
2 10.4 −2.8 f 30 161 167
3 11.3 −2.7 m 20
4 13.2 −2.5 m 31
5 16.6 −2.3 m 30
6 16.9 −2.2 m 30
7 17.5 −2.2 m 29
8 17.8 −2.2 f 22 23
9 18.6 −2.1 m 29
10 19.0 −2.1 f 30 33
11 19.2 −2.1 m 29
12 19.2 −2.1 m 30
13 19.6 −2.0 m 30
14 19.7 −2.0 m 30
Mean* 44.8
SD* 12.4
*Mean and standard deviation of all 2,000 samples.
#Difference from mean (in standard deviation units).
Allele sizes are in CGG repeat number.
Figure 2 PCR analysis of DBS sample 2 in Table 1, a female
with a large premutation allele and a highly methylated
normal allele. A: Capillary electrophoresis profile of PCR analysis.
Arrows indicate alleles of 30, 161 and 167 CGG repeats. The 161 and
167 repeat alleles (arrows at right) represent a premutation allele.
(Somatic mosaicism is presumably responsible for the bifurcation).
B: Methylation analysis reference (no Hpa II digestion) PCR profile of
DBS DNA. C: Methylation analysis PCR profile of Hpa II-digested DBS
DNA. Comparison of B and C illustrates how each allele is protected
from HpaII digestion by methylation. The premutation was split into
two alleles and the analysis suggests that the larger, 167 repeat had
a lower level of methylation than the smaller, 161 repeat allele. The
2 PCR products at approximately 0 CGG repeats represent internal
controls for the methylation analysis.
Table 2 Australian newborn DBS with lowest FMRP levels
Genotype Sex FMRP pM zFMRP# Storage (mo)
full m 0.11 −1.9 47
full m 0.14 −1.9 19
full m 0.35 −1.9 73
full m 0.53 −1.8 38
full m 0.58 −1.8 79
full m 0.64 −1.8 32
nl f 0.77 −1.8 84
nl m 1.45 −1.7 48
nl f 2.32 −1.6 48
Mean* m + f 12.5
SD* 6.5
*Mean and standard deviation of control normal samples (n = 59).
#Difference from mean (in standard deviation units).
nl: normal, full: full mutation.
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the extreme low end of the FMRP distribution (Table 1,
Sample 2) showed a normal allele of 30 repeats and a
large premutation that appeared as two alleles of ap-
proximately 161 and 167 repeats (Figure 2). Methylation
analysis, informed by two HpaII sites on either side of
the CGG repeat [15,16] showed that the normal, 30 re-
peat, allele was highly resistant to Hpa II digestion which
indicated that it was highly (~90%) methylated (Figure 2).
This implied highly skewed X inactivation in which the
normal allele resided on the inactive X chromosome in
most white blood cells in the newborn blood sample
while the premutation resided on the active chromo-
some in most of these cells.
New South Wales newborn DBS samples
We also applied the qFMRP assay in a retrospective study
of 74 newborn DBS that had been stored for an extended
period and included 6 full mutation males as well as 68
normal individuals. This analysis was performed in a
blinded manner to correlate the FMRP levels detected in
the aged newborn DBS with the diagnoses of the fragile X
syndrome that had been made later by the GOLD Service
Hunter Genetics (Newcastle, Australia), after the pheno-
type appeared. The storage time for the full mutation and
normal DBS ranged from 19 to 79 months and from 7 to
84 months, respectively. Table 2 shows the results for the
9 aged newborn DBS with the lowest levels of FMRP. The
FMRP level of the 6 full mutation males in this sample set
was indistinguishable from background and more than 20
Figure 4 Distribution of FMRP levels in 59 newborn DBS from
normal controls in the New South Wales archive. The mean
FMRP value was 12.5 ± 6.5. Storage time for this sample set
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sample set. Analysis of the normal controls in this study
indicated that the amount of detectable FMRP in the DBS
had declined significantly with extended storage (Figure 3)
which shifted the FMRP distribution toward zero (Figure 4).
The only normal sample that approached (0.77 pM) the
level of the fragile X syndrome samples had been stored
for seven years. Despite the loss of detectable FMRP with
DBS storage time, the qFMRP assay identified all of the
affected (full mutation) males. Because of the decline of
detectable FMRP in normal control DBS that could lead to
false positives, the Mann-Whitney analysis and the boxplot
of these results shown in Figure 5 excluded samples that
had been stored for more than 47 months. Samples in this
subset showed a significant separation between normal
(male and female) and full mutation males (P ≤0.001,
U-test).was ≤47 months.Discussion
The distribution of FMRP levels in the sample of 2,000
newborn DBS from the NY State collection (Figure 1)
parallels the profile of 134 non-newborn DBS samples
from individuals of normal phenotype and normal size
CGG repeat alleles that were analyzed previously [12].
The mean FMRP level was considerably higher than
expected–approximately seven-fold higher than in the
previous study of 134 normal individuals. While the
higher white blood cell level in newborns [17] is almost
certainly a contributor to this increase, only about half
of the increase in the average FMRP level is explained by
the predicted increase in white blood cell count. This
suggests that newborns may have increased FMRP ex-
pression in white blood cells. Whatever the explanation,
the increase in the average FMRP level will enhance theFigure 3 Decline in detectable FMRP with DBS storage time.
Samples from normal individuals are plotted according to duration
of storage in months. The formula for the best fit trend line:
y =21.903e-0.028×; R2 = 0.5509.specificity and sensitivity of the qFMRP assay for scree-
ning newborn DBS.
Considering the prevalence of fragile X, it is not sur-
prising that none of the 1,000 samples from males and
1,000 from females lacked FMRP or had an FMRP level
low enough to signal the presence of the fragile X syn-
drome. Although there were clearly no samples in this
set of 2,000 that were from individuals who would de-
velop the fragile X syndrome, we examined the FMR1
CGG region in the DBS samples with FMRP lower thanFigure 5 Boxplot of FMRP values in 63 newborn DBS from New
South Wales archive. Box-plot data are expressed as 25th to 75th
percentile, median, and whiskers to 10th and 90th percentiles with
outliers shown as circles. *P =≤0.001, Mann-Whitney U-test. Storage
time for this sample set was ≤47 months.
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at the low extreme of the distribution. Thirteen of the
14 samples in this group had normal CGG repeat alleles,
which confirmed that these FMRP levels were within the
normal range and that they contained reduced levels of
FMRP due to factors other than CGG repeat length—for
example, due to the variability in the number of white
blood cells in newborns [18].
In contrast one sample (sample 2 in Table 1) appeared
to be at the low extreme of the normal FMRP distribu-
tion due to reduced FMRP expression from a 161/167-
repeat premutation allele. FMR1 alleles of this size are
rare and have reduced levels of FMRP [9,19]. Methyla-
tion analysis (Figure 2) indicated skewed inactivation of
approximately 90% of the X chromosome with the nor-
mal 30-repeat allele. Thus, FMRP expression was pri-
marily from the premutation allele with its reduced
FMRP expression which is probably the explanation for
the low-normal amount of FMRP. The assignment of
this one sample out of 2,000 to the low normal range
is extremely unlikely to have occurred by chance and
demonstrates the potential discriminatory power of this
assay.
The aged DBS from New South Wales newborn
screening collection were very different from the fresh
2,000 DBS from the NY State collection. The former
newborn DBS had been archived for an extended period
and were analyzed for FMRP only after some of the
males represented were later found to have the fragile X
syndrome. The extended storage time reduced the level
of FMRP that could be detected (Figure 3) which shifted
the distribution of FMRP levels toward zero (Figure 4).
The mean normal concentration was approximately half
that of the normal adult population we had previously
analyzed [12] and less than a third of the mean of new-
born DBS that had been stored for only five weeks
(Table 1). The results shown in Table 2 indicate that
extended DBS storage, especially for longer than 48
months, could lead to some overlap between normal and
full mutation. Despite the reduction of detectable FMRP
due to prolonged storage, this retrospective analysis was
a highly effective screen that identified all specimens
from affected (full mutation) males. However, prolonged
storage of newborn DBS (more than 47 months) could
lead to an increase in false positive samples. Thus, the
qFMRP assay will have limited utility for DBS stored for
four years or more. Future retrospective studies with
aged newborn DBS should be performed with samples
that have been stored less than 47 months, and the
levels of FMRP should be compared to those of aged
normal DBS having the same prolonged storage time.
It is likely that the qFMRP assay would be able to pre-
dict cognitive impairment in full mutation females and
distinguish between those that had an IQ <70 and highfunctioning full mutation as well as premutation females.
Studies of FMR1 alleles have shown that the methylation
of specific sites is predictive of intellectual impairment
in full mutation females [20,21]. This methylation is pre-
sumably an indirect measure of FMRP expression and
thus a direct qFMRP analysis is likely to be as predictive
as an assay of FMR1 methylation.
Fragile X does not have a distinctive phenotype in in-
fants and young children and the average age at which
the syndrome is diagnosed in males is 36 months in the
USA and 54 months in Australia [22-24]. While there is
currently no specific treatment for fragile X, early diag-
nosis of the syndrome would allow early therapeutic
intervention for affected children and timely genetic
counseling for their parents. Early diagnosis would be-
come even more critical if pharmacological therapies for
fragile X that are currently in phase 2 or 3 clinical trials
prove effective.
Diagnosis of the fragile X syndrome is currently based
on analysis of the CGG repeat in genomic DNA and DNA
molecular tests have been used in pilot newborn screening
for fragile X [25,26]. However, DNA molecular tests that
determine CGG allele size identify premutation carriers as
well as full mutation individuals. Premutation carriers are
at risk for an adult onset disorder, fragile X associated
tremor/ataxia syndrome (FXTAS) [27]. Since there is
currently no treatment for FXTAS, the identification of
newborns with the premutation complicates the ethics of
fragile X screening by DNA analysis. There are currently
no fragile X newborn screening programs.
Conclusion
Our data show for the first time that it is feasible to mea-
sure FMRP in 3-mm-diameter newborn DBS disks which
are used in mandatory screening for metabolic and here-
ditary diseases. The accurate measurement of FMRP in
these small diameter disks is enhanced by the relatively
high levels of the protein present in neonates, which could
in part be due the high leukocyte count [17,18].
The level of FMRP in newborn is variable and is, on
average, seven times higher than that detected in adults.
Even though the levels of FMRP detected in DBS decrease
with storage time, the qFMRP assay allowed us to identify
all affected males from the set of aged DBS from normal
and fragile X individuals. Our data suggests that the
qFMRP assay could serve as the initial step in a fragile X
newborn screening program. In a second screening step,
characterization of CGG size and/or methylation status of
the FMR1 alleles associated with DBS at the low extreme
of the FMRP distribution would indicate the presence of
the fragile X syndrome. The correlation between highly
reduced or absent FMRP expression and the fragile X syn-
drome is firmly established for males. This correlation is
likely to apply to females as well but further studies will be
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by qFMRP has distinct advantages over techniques that
detect a CGG expansion since it avoids ethical issues asso-
ciated with identification of asymptomatic premutation
carrier infants and is consistent with current newborn
screening technology and cost parameters.
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